Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.

All acellular pertussis vaccines contain pertussis toxoid and induce protection against pertussis. This study investigated the relation between the postvaccination levels of pertussis toxin (PT) serum IgG and protection against pertussis. PT IgG was determined in sera obtained 21-77 days after the third vaccination from 813 children who received 3 doses of pertussis toxoid. The children were followed for 21-33 months after vaccination for the occurrence of pertussis. Of the children, 126 were exposed to pertussis in their households. The median PT IgG concentration was 79 U/mL in those who developed severe pertussis (>/=21 day of paroxysmal cough), 156 U/mL with mild pertussis (<21 days of paroxysmal cough), and 246 U/mL in those who did not develop pertussis (79 vs. 246, P<.0001). Corresponding values in the 687 children with no household exposure were 99, 124, and 155 U/mL, respectively (99 vs. 155, P<.0001). Thus, there is a highly significant correlation between the level of vaccine-induced serum PT IgG and protection against pertussis.

[1]  H. Hallander,et al.  Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. , 1998, Vaccine.

[2]  J. Gornbein,et al.  A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. , 1998, Vaccine.

[3]  J. Robbins,et al.  Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. , 1997, The Journal of pediatrics.

[4]  J. Robbins,et al.  Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. , 1997, The Pediatric infectious disease journal.

[5]  Siber Gr.  Methods for estimating serological correlates of protection. , 1997 .

[6]  P. Mastrantonio,et al.  Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. , 1997, Developments in biological standardization.

[7]  K. Edwards,et al.  Acellular pertussis vaccines for infants. , 1996, The New England journal of medicine.

[8]  W. Blackwelder,et al.  A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.

[9]  W. Blackwelder,et al.  Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. , 1995, Journal of immunological methods.

[10]  M. Pittman,et al.  Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine , 1993, The Pediatric infectious disease journal.

[11]  J. Mezzatesta,et al.  Unrecognized pertussis infection in adolescents. , 1993, American journal of diseases of children.

[12]  M. Granström,et al.  Serological correlates in whooping cough. , 1993, Vaccine.

[13]  J. Cherry,et al.  A Search for Bordetella pertussis Infection in University Students , 1992 .

[14]  W. Blackwelder,et al.  Pertussis antibodies, protection, and vaccine efficacy after household exposure. , 1992, American journal of diseases of children.

[15]  N. Begg,et al.  Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine. , 1991, BMJ.

[16]  J. Taranger,et al.  History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. , 1990, The Journal of pediatrics.

[17]  I. Krantz,et al.  Estimating incidence of whooping cough over time: a cross-sectional recall study of four Swedish birth cohorts. , 1989, International journal of epidemiology.

[18]  Adhocgroupforthestudyofpert.  PLACEBO-CONTROLLED TRIAL OF TWO ACELLULAR PERTUSSIS VACCINES IN SWEDEN?PROTECIVE EFFICACY AND ADVERSE EVENTS , 1988 .

[19]  M. Santosham,et al.  Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. , 1987, The New England journal of medicine.

[20]  M. Pittman.  The concept of pertussis as a toxin‐mediated disease , 1984, Pediatric infectious disease.

[21]  P. Mäkelä,et al.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. , 1983, The Journal of infectious diseases.

[22]  O. Wa,et al.  Diphtheria and tetanus toxoids and pertussis vaccine combined. , 1983 .

[23]  J. Mcgowan,et al.  Epidemiology of pertussis, Atlanta, 1977. , 1981, Jornal de Pediatria.

[24]  J. Regan,et al.  Enrichment medium for the isolation of Bordetella , 1977, Journal of clinical microbiology.

[25]  J. C. Parke,et al.  Quantitative Measurement of “Natural” and Immunization-induced Haemophilus influenzas type b Capsular Polysaccharide Antibodies , 1973, Pediatric Research.

[26]  G. Edsall.  Immunization of adults against diphtheria and tetanus. , 1952, American journal of public health and the nation's health.

[27]  R. M. Atwater.  Prevention of Whooping-cough by Vaccination , 1951, British medical journal.

[28]  J. Ipsen,et al.  Circulating antitoxin at the onset of diphtheria in 425 patients. , 1946, Journal of immunology.